Advertisement
Research Article

In Vivo Targeting of ADAM9 Gene Expression Using Lentivirus-Delivered shRNA Suppresses Prostate Cancer Growth by Regulating REG4 Dependent Cell Cycle Progression

  • Che-Ming Liu equal contributor,

    equal contributor Contributed equally to this work with: Che-Ming Liu, Chia-Ling Hsieh

    Affiliation: Ph.D. Program for Cancer Biology and Drug Discovery, China Medical University and Academia Sinica, Taichung, Taiwan, ROC

    X
  • Chia-Ling Hsieh equal contributor,

    equal contributor Contributed equally to this work with: Che-Ming Liu, Chia-Ling Hsieh

    Affiliations: Graduate Institutes of Cancer Biology, China Medical University, Taichung, Taiwan, ROC, Center for Molecular Medicine, China Medical University Hospital, Taichung, Taiwan, ROC, Department of Biotechnology, Asia University, Wufeng, Taichung, Taiwan, ROC

    X
  • Yun-Chi He,

    Affiliation: Graduate Institutes of Cancer Biology, China Medical University, Taichung, Taiwan, ROC

    X
  • Sen-Jei Lo,

    Affiliation: Graduate Institutes of Cancer Biology, China Medical University, Taichung, Taiwan, ROC

    X
  • Ji-An Liang,

    Affiliation: Division of Radiation Oncology, China Medical University Hospital, Taichung, Taiwan, ROC

    X
  • Teng-Fu Hsieh,

    Affiliations: Graduate Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan, ROC, Division of Urology, Buddhist Tzu-Chi General Hospital, Taichung Branch, Taichung, Taiwan, ROC, Department of Urology, School of Medicine, Buddhist Tzu Chi University, Hualien, Taiwan, ROC

    X
  • Sajni Josson,

    Affiliation: Department of Medicine, Cedars Sinai Medical Center, Los Angeles, California, United States of America

    X
  • Leland W. K. Chung,

    Affiliation: Department of Medicine, Cedars Sinai Medical Center, Los Angeles, California, United States of America

    X
  • Mien-Chie Hung,

    Affiliations: Graduate Institutes of Cancer Biology, China Medical University, Taichung, Taiwan, ROC, Center for Molecular Medicine, China Medical University Hospital, Taichung, Taiwan, ROC, Department of Biotechnology, Asia University, Wufeng, Taichung, Taiwan, ROC, Department of Molecular and Cellular Oncology, M.D. Anderson Cancer Center, University of Texas, Houston, Texas, United States of America

    X
  • Shian-Ying Sung mail

    ssung@mail.cmu.edu.tw

    Affiliations: Ph.D. Program for Cancer Biology and Drug Discovery, China Medical University and Academia Sinica, Taichung, Taiwan, ROC, Graduate Institutes of Cancer Biology, China Medical University, Taichung, Taiwan, ROC, Center for Molecular Medicine, China Medical University Hospital, Taichung, Taiwan, ROC

    X
  • Published: January 16, 2013
  • DOI: 10.1371/journal.pone.0053795

Media Coverage of this Article

Found additional news media or blog coverage for the article? Please let us know.